2 0 RUNNING TITLE: Brain delivery of drugs in Alzheimer's.
, whose action is compromised in age (A et al. 2012) , and more markedly so but this has not been tested, and the importance of P-gp relative to other transporters, especially 1 0 3 members of the SLC superfamily, remains unclear. Amisulpride is predominately positively 1 0 4 charged (98.9%) at physiological pH (pKa 9.37), and is likely a substrate for the organic 1 0 5 cation transporters (OCT) and organic cation transporters novel (OCTN); as observed using 68.6% at 120 minutes ( Figure 3 ). The V d of [ 14 C]sucrose was not significantly different b.End3 cells ( Figure S7 ). The effect of the cationic drug, haloperidol (40μM), on radiolabelled amisulpride 2 1 2 accumulation was also investigated. Incubation of unlabelled haloperidol with 2 1 3
[ 3 H]amisulpride did not yield any significant effects in either cell line ( Figure S9 ). No 2 1 4 significant differences were found for [ 14 C]sucrose between the treatments ( Figure S9 ). by 94% in bEnd.3 cell line at all times (***p<0.001) ( Figure S10 ). No significant differences 2 2 0
were found for [ 14 C]sucrose between the treatments ( Figure S10 ). treatments ( Figure S11 ). The hypothesis that haloperidol uptake is by OCT transporters was hCMEC/D3 cells and by 82% in bEnd.3 cells (***p<0.001) ( Figure S12 ). No significant 2 3 0 differences were found for [ 14 C]sucrose between the treatments ( Figure S12 ). The effects of other cationic drugs -unlabeled pentamidine (100μM), unlabeled efornithine (***p<0.001) ( Figure S13 ). No significant differences were found for [ 14 C]sucrose between 2 4 0 the treatments ( Figure S13 ). utilized.
2 5 0
Lipophilicity
The octanol-saline partition coefficient for [ 3 H]amisulpride was determined to be 2 5 2 0.0422±0.0045 and for [ 3 H]haloperidol was determined to be 0.6678±0.1278. Amisulpride showed molecular interactions inside the binding site of OCT1 in the form of and hydrophobic interactions are represented in pink dotted lines. Amisulpride showed a similar level of interaction with MATE1 transporter with a free energy interactions appeared to play an important role in its interaction with MATE1 compared to its 2 7 6
interaction with OCT1. The interaction of amisulpride was relatively weaker with PMAT amino acid residues Leu62, Leu236 and Ile239 through hydrophobic interactions ( Figure 5C ). Ala67 (Figure S16A , ESI). However, the interaction of haloperidol with PMAT was limited 2 8 6
to single hydrogen bond with Asp34 and hydrophobic interaction with Leu62 ( Figure S16B , 2 8 7 ESI). The molecular docking study revealed that amisulpride was not a substrate for P-gp with a 2 9 1 free energy binding of -1.81 kcal/mol and the molecule was not able to interact favourably 2 9 2 with the binding pocket of P-gp. P-gp substrates, dexamethasone and colchicine, showed notably superior interaction with P-gp with free energy of binding values of -31.83kcal/mol 2 9 4
and -16.07 kcal/mol. Both dexamethasone and colchicine interacted with the binding pocket 2 9 5 employing hydrogen bonds and hydrophobic interactions ( Figure S17 and Table S1 ). [ 3 H]amisulpride was significantly higher than that of wildtype mice in the frontal cortex, but 3 0 5 not the occipital cortex ( Figure 6 ). No differences in paracellular permeability and membrane integrity were observed. All data 3 1 1 are expressed as mean ± S.E.M, n = 4-6 mice, 2 years old. Perfusion time was 10 minutes. 6 sample. Details of the samples can be found in the supplementary information Tables S3 and   3  4  6 S5.
4 7
Individual transporter expression in each brain region between AD and healthy cases is 3 4 8 comparable as the same amount of protein has been loaded into each well. Note this amount 3 4 9
was dependent on the antibody utilized so was variable. Transporter expression in the frontal 3 5 0 cortex was less variable between healthy and AD cases than in the other regions studied with differences were observed, however, further cases are required to explore this more fully.
5 7
Please note it is also likely that transporter expression in caudate nucleus and putamen AD total protein expression is significantly reduced (Table S5 ). The expression of all these BBB our group (Sekhar et al. 2017 ) and OCTN1 and OCTN2 were shown to be expressed in both cell lines in this present study. However, in the presence of amantadine, a substrate for several transporters of organic The absence of any effect of prazosin on [ 3 H]amisulpride uptake in bEnd.3 cells can be vitro inhibitor studies with lopinavir, suggest that amisulpride could be effluxed by PMAT.
1 7
This transporter is expressed on brain capillaries (Figures 7, S19B , S19C and S28) mRNA and protein has also been identified on the luminal and abluminal membrane of
human, mouse and rat brain endothelial cells (Wu et al. 2015) . It is important to highlight that the lack of inhibitor effect may not be conclusive proof of a 4 2 3 lack of substrate interaction with the transporter. It may be that the transporter was not 4 2 4 sufficiently expressed. For example in a recent study, MATE1 mRNA was below the limit of to different binding sites, the non-specificity of the inhibitor, and that amisulpride interacts Haloperidol has been observed to have a high degree of dopamine receptor (D2) occupancy 4 3 4
within the brain at very low doses suggesting that haloperidol is very efficient at crossing the lines. As haloperidol exists predominately (94.8%) as a positively charged drug at and prazosin (OCT1 and 3) , which confirmed the involvement of OCTs at the BBB in 4 4 6 haloperidol transport. The transport of haloperidol from the BBB into the brain is also likely 4 4 7 to be carried out by OCTs since they are expressed at the luminal and abluminal membrane of 4 4 8
the BBB. We also investigated the involvement of ABC transporters in the transport of 4 4 9
haloperidol. For this, ATP was depleted from the cells by incubating them with 10 mM 2- Radiolabelled amisulpride (6.5nM) was also incubated with haloperidol (OCT1 substrate and accumulation. Overall these results may reflect differences in the interaction of amisulpride, 4 6 1 haloperidol and prasozin with specific OCT1 transporter binding sites. in cooperation with P-gp (Hiasa et al., 2006) . Co-localization of MATE1 with members of 5 0 0 the ABC transporter family has previously been reported (Staud et al. 2013) . This suggests that amisulpride was a substrate for MATE 1 and PMAT. Several medications listed in Table   5 0 7
S4 (e.g. citalopram, metoclopramide and loratadine) have previously been identified as OCT1 BBB and/or at an intracellular membrane. Furthermore, the study is of key importance as the 5 1 8
results suggest that the heightened sensitivity to amisulpride observed in older people with The supernatant protein concentration was determined using a BCA assay (Albumin standard, Membranes were incubated overnight at 4°C with primary antibodies in PBS-T (Table S6) . Quantification of protein expression was determined by calculating the intensity ratio of the Data are expressed as mean±SEM. The data was analysed by two-way ANOVA with Holm- Ahlin G., Karlsson J., Pedersen J. M., Gustavsson L., Larsson R., Matsson P., Norinder U., Neurosci. 7, 492-500. disease secondary to abnormal blood-brain barrier integrity? Brain 140, 865-867. Clark-Papasavas C., Dunn J. T., Greaves S., Mogg A., Gomes R., Brownings S., Liu K., et al. Psychiatry 29, 1001-9. Dickens D., Owen A., Alfirevic A., Giannoudis A., Davies A., Weksler B., Romero I. A., 
